Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TScan Therapeutics (TCRX) Return on Sales (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Return on Sales for 6 consecutive years, with 8.95% as the latest value for Q4 2025.

  • Quarterly Return on Sales rose 4326.0% to 8.95% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 12.57% through Dec 2025, up 3232.0% year-over-year, with the annual reading at 12.57% for FY2025, 3232.0% up from the prior year.
  • Return on Sales for Q4 2025 was 8.95% at TScan Therapeutics, up from 14.22% in the prior quarter.
  • The five-year high for Return on Sales was 2.72% in Q4 2023, with the low at 59.07% in Q2 2024.
  • Average Return on Sales over 5 years is 15.16%, with a median of 6.31% recorded in 2021.
  • The sharpest move saw Return on Sales crashed -5143bps in 2024, then surged 4706bps in 2025.
  • Over 5 years, Return on Sales stood at 4.98% in 2021, then dropped by -22bps to 6.05% in 2022, then soared by 55bps to 2.72% in 2023, then tumbled by -1820bps to 52.21% in 2024, then soared by 83bps to 8.95% in 2025.
  • According to Business Quant data, Return on Sales over the past three periods came in at 8.95%, 14.22%, and 12.01% for Q4 2025, Q3 2025, and Q2 2025 respectively.